°øÁö : µµÄìÁõ±Ç°Å·¡¼Ò JASDAQ ½ºÅÄ´Ùµå ½ÃÀå ½Å±Ô »óÀå °ü·Ã ¾È³»

Global Information
ȸ»ç¼Ò°³ | ¹®ÀÇ | ºñ±³¸®½ºÆ®

ÀÏȸ¿ë ¹ÙÀÌ¿À¸®¾×ÅÍ ½ÃÀå : ¼ºÀå, µ¿Çâ, ¿¹Ãø(2020-2025³â)

Single-use Bioreactor Market - Growth, Trends, and Forecast (2020 - 2025)

¸®¼­Ä¡»ç Mordor Intelligence Pvt Ltd
¹ßÇàÀÏ 2020³â 06¿ù »óǰ ÄÚµå 941576
ÆäÀÌÁö Á¤º¸ ¿µ¹®
°¡°Ý
US $ 4,250 £Ü 4,728,000 PDF (Single User License)
US $ 4,750 £Ü 5,284,000 PDF (Team License: Up to 7 Users)
US $ 7,500 £Ü 8,344,000 PDF (Corporate License)


ÀÏȸ¿ë ¹ÙÀÌ¿À¸®¾×ÅÍ ½ÃÀå : ¼ºÀå, µ¿Çâ, ¿¹Ãø(2020-2025³â) Single-use Bioreactor Market - Growth, Trends, and Forecast (2020 - 2025)
¹ßÇàÀÏ : 2020³â 06¿ù ÆäÀÌÁö Á¤º¸ : ¿µ¹®

¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹®¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹®¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

½ÃÀåÀº Á¦Ç° Á¾·ù(ÀÏȸ¿ë ¹ÙÀÌ¿À¸®¾×ÅÍ ½Ã½ºÅÛ, ¹Ìµð¾î¹é, ¿©°ú ¾î¼Àºí¸®, ±âŸ Á¦Ç°), ¼¼Æ÷ Á¾·ù(Æ÷À¯·ù ¼¼Æ÷, ¼¼±Õ, È¿¸ð, ±âŸ ¼¼Æ÷ Á¾·ù), ºÐÀÚ Á¾·ù, ÃÖÁ¾»ç¿ëÀÚ, Áö¿ª¿¡ ±Ù°ÅÇØ ¼¼ºÐÈ­µÇ°í ÀÖ½À´Ï´Ù.

½ÃÀå °³¿ä

¼¼°èÀÇ ÀÏȸ¿ë ¹ÙÀÌ¿À¸®¾×ÅÍ ½ÃÀåÀº ¿¹Ãø±â°£ Áß 15.5%ÀÇ CAGRÀ» ³ªÅ¸³¾ Àü¸ÁÀÔ´Ï´Ù. ½ÃÀå ¼ºÀå ÃËÁø¿äÀο¡´Â ¾÷°èÀÇ ÀÏȸ¿ë ±â¼ú(SUT)ÀÇ ½Å¼ÓÇÑ Ã¤¿ë, ºñ¿ë È¿À²°ú ´Ù¿îŸÀÓ ´ÜÃà, ½ÅÁ¦Ç° ¹ß¸Å µîÀÌ ÀÖ½À´Ï´Ù.

ÀÏȸ¿ë ¹ÙÀÌ¿À¸®¾×ÅÍ »ç¿ë¿¡ ´ëÇÑ ¾÷°èÀÇ °æÇâÀº ÇöÀç ½ºÅÜÀÇ Á߿伺, Á¦Ç° °¡Ä¡ ¹× Á¦Ç° °³¹ß°ú »ý»ê ½Ã°£¿¡ ¿µÇâÀ» ¹Þ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ÀÏȸ¿ë ¹ÙÀÌ¿À¸®¾×ÅÍ´Â ÀÇ·á ºÐ¾ß·ÎºÎÅÍ ¼ö¿ä°¡ ³ô½À´Ï´Ù. µû¶ó¼­ ÀÌ·¯ÇÑ ¸®¾×ÅÍ´Â Á¦¾àȸ»ç¿¡ ÀÇÇØ ä¿ëµÇ°í ÀÖÀ¸¸ç, ǰÁú¿¡ ´ëÇØ ±³¼·ÇÏÁö ¾Ê°í ÀǾàǰÀ» Á¦Á¶Çϰí ÀÖ½À´Ï´Ù. ÀÏȸ¿ë ¹ÙÀÌ¿À¸®¾×ÅÍ Ã¤¿ëÀÇ ÃÖ´ë ÀÌÁ¡ Áß Çϳª´Â À¯¿¬¼ºÀÔ´Ï´Ù. ´ÙÁ¦Çü ½Ã¼³·ÎÀÇ °æÇâÀÌ °­ÇØÁö¸é¼­ °°Àº ½Ã¼³À» »ç¿ëÇØ ´Ù¸¥ ÀǾàǰÀ» ÃÖ¼ÒÇÑÀÇ ½Ã°£°ú ÃÖ¼ÒÇÑÀÇ ºñ¿ëÀ¸·Î »ý»êÇÏ´Â °ÍÀÌ ¿ä±¸µÇ°í ÀÖ½À´Ï´Ù.

±×·¯³ª ¾î´À ½ÃÁ¡¿¡ ÇÃ¶ó½ºÆ½ Á¦Ç°°ú ÀÏȸ¿ë ¼Ò¸ðǰÀÇ ¹Ýº¹ ºñ¿ëÀ¸·Î ¼³ºñ ÅõÀÚ¾×À» ¿ôµ½´Ï´Ù. °íÁ¤ ½ºÅ×Àθ®½º°­ Àåºñ´Â ¼³Ä¡¿Í À¯Áö°ü¸® ¸é¿¡¼­ Ãʱ⠺ñ¿ëÀÌ ³ôÁö¸¸, ÀÏȸ¿ë ¹ÙÀÌ¿À¸®¾×ÅÍ(SUB)ÀÇ Á¤±âÀûÀÎ °æºñ°¡ ³ô´Ù´Â °ÍÀ» ¾Ë ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ ¹æ´ëÇÑ ¾çÀÇ ºÒ¿ëǰÀ» ÀûÀýÈ÷ ó¸®Çϱâ À§Çؼ­´Â ³ôÀº ºñ¿ëÀÌ µå´Â °æ¿ì°¡ ÀÖ½À´Ï´Ù.

Á¶»ç ¹üÀ§

ÀÏȸ¿ë ¹ÙÀÌ¿À¸®¾×ÅÍ´Â ÇöÀç ¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö Á¦Á¶ ½Ã¼³ÀÇ ÇʼöÀûÀÎ ºÎºÐÀÌ µÇ°í ÀÖ½À´Ï´Ù. Á¦Á¶ ±â¼úÀÇ Áö¼ÓÀû Á¦Ç° Çõ½Å°ú ¿¬±¸°³¹ßºñ Áõ°¡´Â ÇÁ·Î¼¼½º Àüü¸¦ °³¼±Çϰí, °íǰÁú Á¦Ç°À» Á¦°øÇϱâ À§ÇÑ ÁÖ¿ä ÃßÁø·ÂÀ¸·Î¼­ ±â´ÉÇÕ´Ï´Ù. ±×·Î ÀÎÇØ ½ºÅ×Àθ®½º°­ ¹ÙÀÌ¿À¸®¾×ÅͷκÎÅÍ ÀÏȸ¿ë ¹ÙÀÌ¿À¸®¾×ÅÍ·ÎÀÇ À̵¿ÀÌ ¿ëÀÌÇØÁý´Ï´Ù. ÀÏȸ¿ë ¹ÙÀÌ¿À¸®¾×ÅÍ´Â ºñ±³Àû ¾ÈÀüÇϰí, ½ÉÇÃÇϰí, À¯¿¬¼ºÀÌ ÀÖ½À´Ï´Ù. µû¶ó¼­ ±× »ç¿ëÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù.

¼¼°èÀÇ ÀÏȸ¿ë ¹ÙÀÌ¿À¸®¾×ÅÍ(Single-use Bioreactor) ½ÃÀåÀ» Á¶»çÇßÀ¸¸ç, ½ÃÀå °³¿ä, Á¦Ç° Á¾·ùº°¡¤¼¼Æ÷ Á¾·ùº°¡¤ºÐÀÚ Á¾·ùº°¡¤ÃÖÁ¾»ç¿ëÀÚº°¡¤Áö¿ªº° ½ÃÀå µ¿Çâ, ½ÃÀå ±Ô¸ð ÃßÁ¤°ú ¿¹Ãø, ½ÃÀå ¼ºÀå ÃËÁø¡¤ÀúÇØ¿äÀÎ ¹× ½ÃÀå ±âȸ ºÐ¼®, ½ÃÀå Á¡À¯À², °æÀï »óȲ, ÁÖ¿ä ±â¾÷ °³¿ä µîÀÇ Á¤º¸¸¦ Á¦°øÇÕ´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼­·Ð

  • Á¶»ç ¼º°ú
  • Á¶»ç °¡Á¤
  • Á¶»ç ¹üÀ§

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ½ÃÀå ¿ªÇÐ

  • ½ÃÀå °³¿ä
  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
    • ¾÷°èº° ÀÏȸ¿ë ±â¼ú(SUT)ÀÇ ½Å¼ÓÇÑ Ã¤¿ë
    • ºñ¿ë È¿À²°ú ´Ù¿îŸÀÓ ´ÜÃà
    • ½ÅÁ¦Ç° ¹ß¸Å
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
    • ³ôÀº °æ»ó °æºñ
    • ÀûÁ¤ Á¦Á¶ ±âÁØÀÇ ±âÁØÀ» ÃæÁ·½ÃŰ´Â ¹®Á¦
  • Porter's Five Forces ºÐ¼®

Á¦5Àå ½ÃÀå ¼¼ºÐÈ­

  • Á¦Ç° Á¾·ùº°
    • ÀÏȸ¿ë ¹ÙÀÌ¿À¸®¾×ÅÍ ½Ã½ºÅÛ
    • ¹Ìµð¾î¹é
    • ¿©°ú ¾î¼Àºí¸®
    • ±âŸ Á¦Ç°
  • ¼¼Æ÷ Á¾·ùº°
    • Æ÷À¯·ù ¼¼Æ÷
    • ¹ÚÅ׸®¾Æ
    • È¿¸ð
    • ±âŸ ¼¼Æ÷Çü
  • ºÐÀÚ Á¾·ùº°
    • ¹é½Å
    • ´ÜÀÏŬ·ÐÇ×ü
    • Áٱ⼼Æ÷
    • ÀçÁ¶ÇÕ ´Ü¹éÁú
    • ±âŸ ºÐÀÚ Á¾·ù
  • ÃÖÁ¾»ç¿ëÀÚº°
    • Á¦¾à ¹× ¹ÙÀÌ¿ÀÀǾàǰ »ê¾÷
    • ÀÓ»ó½ÃÇè¼öʱâ°ü(CRO)
    • ±âŸ ÃÖÁ¾»ç¿ëÀÚ
  • Áö¿ªº°
    • ºÏ¹Ì
    • À¯·´
    • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • ³²¹Ì

Á¦6Àå °æÀï »óȲ

  • ±â¾÷ °³¿ä
    • ABEC Inc.
    • Celltainer
    • Distek Inc.
    • Eppendorf AG
    • GE Healthcare
    • Merck KGaA
    • OmniBRx Biotechnologies
    • Pall Corporation
    • Sartorius AG
    • Thermo Fisher Scientific
KSM 20.06.25

The Market is Segmented on the basis of Type of Product (Single-use Bioreactor Systems, Media Bags, Filtration Assemblies, and Other Products), Cell Type (Mammalian Cell, Bacteria, Yeast, and Other Cell Types), Molecule Type, End User, and Geography.

Market Overview

The global single-use bioreactor market is expected to witness a CAGR of 15.5% during the forecast period. Certain factors that are driving the market's growth include rapid adoption of single-use technologies (SUTs) by the industry, cost-effectiveness and lower downtime, and launch of new products.

The inclination of the industry toward using single use bioreactors is currently being influenced by the criticality of the step, the value of the product, and the time for product development and production. These single-use bioreactors are in high demand, from the medical sector. These reactors are thus adopted by the pharmaceutical, companies to manufacture drugs without any negotiations on their quality. One of the biggest advantages of the adoption of single use bioreactors is the flexibility. The increasing trend toward multi drug facilities demands the production of different drugs, using the same facility, in minimum time and with minimum costs.

However, at some point, the capital investment is found to be exceeded by the repetitive cost for plasticware and single-use consumables. So, although fixed stainless steel equipment have high upfront costs in terms of installation and maintenance, the regular recurring expenses for single-use bioreactors (SUBs) is found to be higher. In addition, high costs may be involved in proper waste management of the vast amounts of disposables.

Scope of the Report

Single-use bioreactors, also known as disposable bioreactors, have now become an integral part of the biotechnology manufacturing facilities. Continuous product innovation and increasing R&D expenditure in manufacturing technology act as key drivers in improving the overall process and providing high-quality products. This facilitates the transition from stainless steel bioreactors to single-use bioreactors. Single-use bioreactors are comparatively safe, simple, and flexible. Thus, their usage is increasing.

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rapid Adoption of Single-use Technologies (SUTs) by the Industry
    • 4.2.2 Cost Effectiveness and Lower Downtime
    • 4.2.3 Launch of New Products
  • 4.3 Market Restraints
    • 4.3.1 High Regular Recurring Expenses
    • 4.3.2 Issues with Meeting the Standards of Good Manufacturing Practices
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5. MARKET SEGMENTATION

  • 5.1 Type of Product
    • 5.1.1 Single-use Bioreactor Systems
    • 5.1.2 Media Bags
    • 5.1.3 Filtration Assemblies
    • 5.1.4 Other Products
  • 5.2 Cell Type
    • 5.2.1 Mammalian Cell
    • 5.2.2 Bacteria
    • 5.2.3 Yeast
    • 5.2.4 Other Cell Types
  • 5.3 Molecule Type
    • 5.3.1 Vaccines
    • 5.3.2 Monoclonal Antibodies
    • 5.3.3 Stem Cells
    • 5.3.4 Recombinant Proteins
    • 5.3.5 Other Molecule Types
  • 5.4 End User
    • 5.4.1 Pharmaceutical and Biopharmaceutical Industries
    • 5.4.2 Contract Research Organizations (CRO)
    • 5.4.3 Other End Users
  • 5.5 Geography
    • 5.5.1 North America
      • 5.5.1.1 United States
      • 5.5.1.2 Canada
      • 5.5.1.3 Mexico
    • 5.5.2 Europe
      • 5.5.2.1 Germany
      • 5.5.2.2 United Kingdom
      • 5.5.2.3 France
      • 5.5.2.4 Italy
      • 5.5.2.5 Spain
      • 5.5.2.6 Rest of Europe
    • 5.5.3 Asia-Pacific
      • 5.5.3.1 China
      • 5.5.3.2 Japan
      • 5.5.3.3 India
      • 5.5.3.4 Australia
      • 5.5.3.5 South Korea
      • 5.5.3.6 Rest of Asia-Pacific
    • 5.5.4 Middle East & Africa
      • 5.5.4.1 GCC
      • 5.5.4.2 South Africa
      • 5.5.4.3 Rest of Middle East & Africa
    • 5.5.5 South America
      • 5.5.5.1 Brazil
      • 5.5.5.2 Argentina
      • 5.5.5.3 Rest of South America

6. COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 ABEC Inc.
    • 6.1.2 Celltainer
    • 6.1.3 Distek Inc.
    • 6.1.4 Eppendorf AG
    • 6.1.5 GE Healthcare
    • 6.1.6 Merck KGaA
    • 6.1.7 OmniBRx Biotechnologies
    • 6.1.8 Pall Corporation
    • 6.1.9 Sartorius AG
    • 6.1.10 Thermo Fisher Scientific
Back to Top
ÀüÈ­ ¹®ÀÇ
F A Q